AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02269670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: Given PO
Study NCT03356925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xpert Ultra Point of Care testing
Description: The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
Study NCT01667601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
Study NCT01667601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program
Description: The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
Study NCT01667601 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-based program
Description: The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
Study NCT01667601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation group
Description: A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
Study NCT01667601 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation group
Description: A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
Study NCT00234065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
Study NCT00234065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
Study NCT02889991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Dry Needling
Description: This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear.
Study NCT02889991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity Dry Needling
Description: Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
Study NCT02889991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Mechanotransduction Dry Needling
Description: The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session.
Study NCT02889991 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Technique Placebo of Dry Needling
Description: Technique with a total duration of 3 minutes per session:~* To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~* Monitor longitudinally taut band, with index and middle fingers.~* Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~* Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~* Remove the bridles and perform hemostasis with cotton.~* We will give end to the technique placebo of dry needling.
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg Q4W ±2 days
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib (AZD2281) given orally at 300 mg BD
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan
Description: Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib
Description: cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 (ceralasertib)
Description: AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 (ceralasertib)
Description: AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 (ceralasertib) (240 mg or 160 mg)
Description: AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
Study NCT03334617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 (ceralasertib) 7 days monotherapy
Description: AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
Study NCT03195010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Undergo lower dose platelet transfusion
Study NCT03195010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Undergo higher dose platelet transfusion
Study NCT03477435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff training and academic detailing
Description: Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.
Study NCT00653640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: body weight supported treadmill training
Description: BWSTT for 12 weeks, 3 times per week
Study NCT00653640 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: traditional physical therapy
Description: traditional PT for 12 weeks, 3 times per week
Study NCT00725296 — intervention group
Intervention type: BIOLOGICAL
Intervention: Remicade (Infliximab)
Description: Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
Study NCT01031810 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tranylcypromine
Description: MAO-Inhibitor 60mg-120mg
Study NCT01456026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycated beta-lactoglobulins.
Description: oral, 20 g, single administration
Study NCT01456026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-glycated beta-lactoglobulins
Description: 20 g, oral, single administration,
Study NCT01083251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon + Vitamin D
Description: 180 mcg/week + 400 IUX2/day
Study NCT01083251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon
Description: 180 mcg/week
Study NCT01083251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sebivo
Description: Telbivudine 600 mg daily
Study NCT01083251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir+ vitamin d
Description: entecavir 1 mg daily+ vitamin d
Study NCT04290156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint visits
Description: The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
Study NCT02932488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
Study NCT03651154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypovolemic Phlebotomy
Description: Removal of 7-10ml/kg of blood from participant, as tolerated after patient is under anesthesia, before liver resection start time
Study NCT01906216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
Study NCT01906216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
Study NCT01906216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response.
Study NCT03066648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
Study NCT03066648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
Study NCT03066648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
Study NCT02109718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Dressings with Petrolatum Jelly
Description: participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
Study NCT02109718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine Gauze Dressing Group
Description: Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
Study NCT03066648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
Study NCT04798911 — intervention group
Intervention type: OTHER
Intervention: Phase 1 Observational Interviews
Description: Qualitative interviews with patients with SS
Study NCT03966417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Continuous exercise training 2 times per week for a period of 12 weeks.
Study NCT01896128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Study NCT01896128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive pill manufactured to mimic Armodafinil 150 mg tablet
Study NCT01809054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arixtra
Study NCT01809054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic compression stockings
Description: Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
Study NCT01809054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02050906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
Study NCT02050906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
Study NCT02050906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavioral activity counseling
Description: Undergo behavioral activity and nutritional counseling
Study NCT02050906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone based counseling
Description: Undergo behavioral activity and nutritional counseling
Study NCT02050906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02050906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02050906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02050906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03003533 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-8011
Description: A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
Study NCT01356875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSC
Description: The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
Study NCT01356875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIDRA/VPA
Description: In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
Study NCT02611466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7962
Description: Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Study NCT02611466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Study NCT02611466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Study NCT03812913 — intervention group
Intervention type: BEHAVIORAL
Intervention: psychological evaluation
Description: * Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~* Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning.
Study NCT01538550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Description: Flexible sigmoidoscopy screening is offered once only
Study NCT01538550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iFOBT
Description: Biennial screening with iFOBT
Study NCT02415933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trickle Up
Description: Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~* Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~* Provision of seed grants to assist in business start-ups through microfinance loans;~* One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~* Trainings on financial planning and household livelihoods.
Study NCT02415933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trickle Up Plus
Description: In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage).
Study NCT01294358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
Study NCT03613454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splenic artery embolization with vascular embolic coils
Description: Splenic artery embolization with vascular embolic coils
Study NCT00570856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid 5 mg/day
Study NCT00570856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo similar to the folic acid tablets, 1/day
Study NCT03565211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring
Description: A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
Study NCT03947606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASCADE (CAre Supporters Coached to be Adept DEcision partners)
Description: CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, nurse coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training.
Study NCT03811197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling via face to face meeting
Description: All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).